NBIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Neurocrine Biosciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.08.
Neurocrine Biosciences's long-term debt to total assets ratio increased from Dec. 2022 (0.04) to Dec. 2023 (0.08). It may suggest that Neurocrine Biosciences is progressively becoming more dependent on debt to grow their business.
The historical data trend for Neurocrine Biosciences's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial | 0.07 | 0.24 | 0.21 | 0.04 | 0.08 |
Neurocrine Biosciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial | 0.04 | 0.11 | 0.03 | 0.03 | 0.08 |
Neurocrine Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
LT Debt to Total Assets (A: Dec. 2023 ) | = | Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 ) | / | Total Assets (A: Dec. 2023 ) |
= | 258.3 | / | 3251.4 | |
= | 0.08 |
Neurocrine Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
LT Debt to Total Assets (Q: Dec. 2023 ) | = | Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 ) | / | Total Assets (Q: Dec. 2023 ) |
= | 258.3 | / | 3251.4 | |
= | 0.08 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (NAS:NBIX) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Thank you for viewing the detailed overview of Neurocrine Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Charles Gorman | officer: Sr VP, Business Development | 12790 EL CAMINO REAL, SAN DIEGO CA 92130 |
William H Rastetter | director | 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121 |
Kyle Gano | officer: Chief Business Dev Officer | NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Eiry Roberts | officer: Chief Medical Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130 |
Julie Cooke | officer: Chief Human Resources Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Gary A Lyons | director, officer: President and CEO | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Darin Lippoldt | officer: Chief Legal Officer | C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Jude Onyia | officer: Chief Scientific Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
David W. Boyer | officer: Chief Corp. Affairs Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Ingrid Delaet | officer: Chief Regulatory Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Matt Abernethy | officer: Chief Financial Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121 |
Eric Benevich | officer: Chief Commerical Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130 |
Christine A Poon | director | C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
Malcolm Lloyd-smith | officer: Chief Regulatory Officer | 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Stephen A Sherwin | director | C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By GuruFocus Research • 12-10-2023
By GuruFocus Research • 01-12-2024
By PRNewswire • 10-05-2023
By GuruFocus Research • 09-14-2023
By PRNewswire • 01-17-2024
By GuruFocus Research • 10-05-2023
By GuruFocus Research • 12-25-2023
By GuruFocus Research • 12-02-2023
By GuruFocus Research • 11-01-2023
By GuruFocus Research • 12-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.